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http://www.actaneurocomms.org/content/2/1/150RESEARCH Open AccessAltered lipid levels provide evidence for myelin
dysfunction in multiple system atrophy
Anthony S Don1, Jen-Hsiang T Hsiao2, Jonathan M Bleasel2, Timothy A Couttas1, Glenda M Halliday2,3
and Woojin Scott Kim2,3*Abstract
Multiple system atrophy (MSA) is a rapidly-progressive neurodegenerative disease characterized by parkinsonism,
cerebellar ataxia and autonomic failure. A pathological hallmark of MSA is the presence of α-synuclein deposits in
oligodendrocytes, the myelin-producing support cells of the brain. Brain pathology and in vitro studies indicate that
myelin instability may be an early event in the pathogenesis of MSA. Lipid is a major constituent (78% w/w) of
myelin and has been implicated in myelin dysfunction in MSA. However, changes, if any, in lipid level/distribution
in MSA brain are unknown. Here, we undertook a comprehensive analysis of MSA myelin. We quantitatively
measured three groups of lipids, sphingomyelin, sulfatide and galactosylceramide, which are all important in myelin
integrity and function, in affected (under the motor cortex) and unaffected (under the visual cortex) white matter
regions. For all three groups of lipids, most of the species were severely decreased (40–69%) in affected but not
unaffected MSA white matter. An analysis of the distribution of lipid species showed no significant shift in fatty acid
chain length/content with MSA. The decrease in lipid levels was concomitant with increased α-synuclein expression.
These data indicate that the absolute levels, and not distribution, of myelin lipids are altered in MSA, and provide
evidence for myelin lipid dysfunction in MSA pathology. We propose that dysregulation of myelin lipids in the
course of MSA pathogenesis may trigger myelin instability.
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MSA white matterIntroduction
Multiple system atrophy (MSA) is a fatal neurodegenera-
tive disease characterized by parkinsonism, cerebellar
ataxia and autonomic failure. The disease affects older in-
dividuals with an incidence in the 50–99 year age group of
3 per 100,000 [1,2]. The mean survival after diagnosis is
9 years [3,4]. MSA is defined histopathologically by the ac-
cumulation of α-synuclein protein mainly in the cytoplasm
of oligodendrocytes, the myelin producing support cells of
the central nervous system [5]. These glial cytoplasmic
inclusions (GCIs) concentrate in the striatonigral system,
olivopontocerebellar system and autonomic nuclei of the
brain stem and spinal chord [6,7]. Neurodegeneration in
these areas is thought to follow loss of trophic and* Correspondence: w.kim@unsw.edu.au
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unless otherwise stated.metabolic support provided by ensheathing oligodendro-
cytes [8-10].
The pathology of MSA contrasts with Parkinson’s
disease (PD) and dementia with Lewy bodies (DLB)
where α-synuclein accumulation and toxicity occurs in
neurons. The reason for this fundamental difference in
cellular focus remains poorly understood. In further
contrast to PD/DLB, no pathogenic mutations or risk-
conferring loci on the α-synuclein gene, SNCA, have
been associated with MSA [11-14]. Thus there is a need
to identify novel oligodendrocyte-specific pathways
underlying the early pathogenesis of this disease. In this
respect, recent progress in the study of oligodendrocyte
lipid handling and myelin maintenance heralds a prom-
ising advance.
Disruption of myelin structural proteins has been ob-
served preceding visible GCIs in postmortem samples of
MSA patients [15], suggesting that myelin instability may
be an early event in the pathogenesis of MSA. Myelin. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Don et al. Acta Neuropathologica Communications 2014, 2:150 Page 2 of 14
http://www.actaneurocomms.org/content/2/1/150stability in turn is dependent on the content and inter-
association of its lipid constituents, particularly cholesterol
and the ceramide-derived sphingolipids sphingomyelin,
sulfatide and galactosylceramide [16-19]. Lipid homeosta-
sis is increasingly recognized as a crucial factor for normal
brain function and growing evidence shows that altered
lipid levels and/or distribution are contributory factors in
a number of neurodegenerative diseases. Recently, the
lipid transporter ABCA8 was shown to stimulate sphingo-
myelin production in oligodendrocytes and likely to have a
role in myelin processing and maintenance [20]. These
data provide strong impetus for investigation of myelin
lipid dysregulation in MSA pathology.
Although lipid constitutes 78% of myelin [21] and
myelin dysregulation is recognized as an important early
pathological event in MSA [15], changes in lipid level/
distribution in MSA brain is unknown. In this study we
assess the quantitative changes in sphingomyelin and the
important structural myelin lipids sulfatide and galacto-
sylceramide in a MSA-affected and unaffected brain re-
gion. Galactosylceramide is formed in oligodendrocytes
through the action of ceramide galactosyltransferase
(CGT) [22,23]. Galactosylceramide may then be further
modified to sulfatide through the action of a specific sul-
fotransferase (Figure 1). Thus we chose to investigate
these lipids as an indicator of oligodendrocyte-specific
myelin lipid metabolism. We hypothesize that regulation
of these lipid species is altered in MSA pathogenesis,
inducing myelin instability and disruption of proteins
associated with the lipid membrane.
Materials and methods
Human brain tissues
Human brain tissues were obtained from the Sydney
Brain Bank and NSW Tissue Resource Centre, part of
the Australian Brain Bank Network funded by the
National Health and Medical Research Council of
Australia. Ethics approval was from the University of
New South Wales Human Research Ethics Committee.
Frozen brain tissues from 8 MSA cases and 10 controls
were used in this study. MSA brains were clinically and
pathologically diagnosed using international diagnostic
criteria [24], and were free of Lewy bodies. Controls
were free of significant neuropathology. Clinical infor-
mation for each case including gender, age at death,
postmortem interval (PMI), and disease duration is
provided in Table 1. The mean age of control and MSA
subjects was 77.4 and 67.8 respectively (p = 0.02), which
is a potential limitation of the present study cohort. The
mean PMI was 21.4 and 16.9 respectively (p = 0.45). Ap-
proximately 50 mg of brain tissue from anatomically
specified regions were collected using a 3-mm stainless
steel biopsy needle from frozen brain slices (dissected on
a bed of dry-ice).Detection of GCIs
Formalin-fixed coronal blocks of white matter and over-
lying motor cortex were paraffin-embedded, cut at 10 μm
on a microtome, and mounted on 3-aminopropyltriet
hoxysilane-coated slides. Following pretreatment with 99%
formic acid for 3 min, immunoperoxidase staining was per-
formed using antibodies to α-synuclein (mouse mAb42, BD
Transduction Labs, USA; diluted 1:100) and an avidin-
biotin-peroxidase detection system (Vector Laboratories,
Burlingame, CA, USA). Sections were counterstained with
0.5% cresyl violet to identify cell constituents. Labeled sec-
tions were evaluated and photographed using an Olympus
BX51 fluorescence microscope fitted with specific filter
systems and a computerized image analysis system (SPOT
camera, Image Pro Plus software).
Lipid assay
Lipids were quantified using Liquid Chromatography-
tandem Mass Spectrometry (LC-MS/MS). Brain tissue
samples were accurately weighed, i.e. 20 mg wet weight,
and lipids were extracted from brain tissues according to a
previously published one-phase extraction protocol [25].
Lipids were resolved and quantified by LC-MS/MS, as
described previously [26], with the exception that 1250
rather than 250 pmoles C12:0 sphingomyelin (Avanti
Polar Lipids, AL, USA) internal standard was added to
each sample. C12:0 sulfatide and C12:0 galactosylceramide
internal standards were added at 250 pmoles/sample. Data
processing was carried out using the MMSAT program
[26] and the detected sphingomyelin and sulfatide spe-
cies were verified as conforming to a previously identi-
fied quadratic elution profile [27]. Lipids, expressed as
ratios to the relevant internal standard, were quantified
using standard curves prepared with sphingomyelin,
galactosylceramide, and sulfatide external standards
(Avanti Polar Lipids).
RNA isolation, reverse transcription and quantitative PCR
RNA was isolated using TRI Reagent (Sigma, Castle Hill,
NSW, Australia) following the manufacturer’s protocol
from control (n = 10) and MSA (n = 8) tissues. All proce-
dures were carried out using RNase-free reagents and
consumables. Five micrograms of RNA was reverse tran-
scribed into cDNA using Moloney-murine leukemia
virus reverse transcriptase and random primers (Pro-
mega, Annandale, NSW, Australia) in a 20 μl reaction
volume. cDNA was used as a template in the quantita-
tive real-time PCR (qPCR) assay, which was carried out
using a Mastercycler ep realplex S (Eppendorf ) and the
fluorescent dye SYBR Green (Bio-Rad), following the
manufacturer’s protocol. Briefly, each reaction (20 μl)
contained 1x RealMasterMix, 1x SYBR green, 5 pmoles
of primers and 1 μl of template. Amplification was car-







Figure 1 Analysis of MSA brain tissues. Analysis of cells using Nissl staining and GCIs using α-synuclein immunohistochemistry in the white
matter underlying the motor cortex of MSA and control brain (A,B). Despite obvious α-synuclein accumulation in GCIs only in MSA, no significant
cell loss or other tissue alterations were detected. The biosynthetic pathway of myelin lipids sphingomyelin, sulfatide and galactosylceramide (C).
Extracted ion chromatograms for sphingomyelin, sulfatide and galactosylceramide species (D). Total and extracted ion chromatograms are shown
for C12:0 internal standards, as well as native C18:0 and C24:1 variants for each lipid class, in a control MC white matter tissue sample. Individual
MS scans are shown rather than smoothed peaks. Each individual ion peak was comprised of a minimum of 10 MS scans.
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The level of expression was calculated using the com-
parative threshold cycle (Ct) value method using the for-
mula 2−ΔΔCt (where ΔΔCt =ΔCt sample – ΔCt reference).
Protein extraction
To 50 mg tissue, 250 μL of ice-cold hypotonic buffer
(250 mM sucrose, 10 mM HEPES (pH 7.4), 1 mM EDTA)
containing complete protease inhibitors (1 mM benzami-
dine, 1 μg/mL leupeptin, 1 μg/mL aprotinin, 1 μg/mL
pepstatin-A; Roche Applied Science, Castle Hill, NSW,Australia) was added. Tissues were dounced 20 times in
microfuge tubes using tight pestles (Sigma, Castle Hill,
NSW, Australia) while on ice. The tubes were centrifuged
at 800 g for 10 min at 4°C and the supernatants were
transferred to new tubes and stored at −20°C.
Western blotting
Protein concentrations were determined using BCA pro-
tein assay. Equal amounts of protein from control (n = 10)
and MSA (n = 8) samples were separated on SDS-PAGE
gels (12% acrylamide) and transferred onto 0.45 μm nitro-
cellulose membranes at 100 volts for 30 min. Membranes
were blocked overnight at 4°C in PBS containing 5% non-
fat dry milk and probed with primary antibody (1/1000 di-
lution) at 4°C overnight. The membranes were washed
three times in PBS containing 0.1% Tween-20 and then
Table 1 Demographics of MSA and control cases
Brain ID Age Gender PMI (h) MSA-P/MSA-C Disease
duration (y)
MSA
MSA1 61 male 21 MSA-P 4
MSA2 82 male 8 MSA-P 7
MSA3 64 male 22 MSA-P 8
MSA4 61 male 7 MSA-P 2
MSA5 62 male 31 MSA-C 10
MSA6 71 female 19 MSA-P 6
MSA7 74 male 16 MSA-P 10
MSA8 67 male 11 MSA-P 8
Control
Con1 78 female 37 N/A N/A
Con2 82 female 7.5 N/A N/A
Con3 69 male 13.5 N/A N/A
Con4 85 male 9 N/A N/A
Con5 65 male 14.5 N/A N/A
Con6 68 male 45.5 N/A N/A
Con7 73 male 38.5 N/A N/A
Con8 88 male 9 N/A N/A
Con9 85 female 10 N/A N/A
Con10 81 male 29 N/A N/A
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ary antibody (Dako, Carpinteria, CA, USA, 1/2000 dilution)
for 2 h. Signals were detected using enhanced chemilumin-
escence (ECL, GE Healthcare, Buckinghamshire, UK) and
X-ray films. The signal intensity was quantified using NIH
ImageJ software.
Statistical analysis
MSA and control human tissue samples examined were
n = 8 and n = 10 respectively. Data presented are
expressed as mean ± SE shown by the error bars; statis-
tical outliers, identified using the ROUT method with
GraphPad PRISM software (Q =1%), were excluded
from the analysis. Statistical significance was analyzed
using the Student’s t test with a p <0.05 considered
significant.
Results
Analysis of MSA brain tissues
To determine if altered white matter lipid levels are a
contributory factor in MSA pathogenesis we undertook
a case–control analysis of lipids in an affected and un-
affected white matter region. The affected region was
the white matter underlying the primary motor cortex
(MC) from the most superior and medial aspect of the
coronal slice. This region in MSA has GCIs but nosignificant cell loss or alteration in tissue composition
(Figure 1A,B), whereas the white matter underlying the
visual cortex (VC) is unaffected by MSA pathology and
is commonly used as a disease-unaffected control region
[28]. We extracted white matter lipids from freshly-
frozen brain and analyzed sphingomyelin, sulfatide and
galactosylceramide, three of the major lipids in myelin
(Figure 1C), using LC-MS/MS. The chromatograms for
major sphingomyelin, sulfatide and galactosylceramide
species are shown to indicate lipid measurement quality
(Figure 1D).
Decreased sphingomyelin levels in MSA white matter
A bubble plot shows the decrease in volume size (indica-
tive of lipid amount) of individual sphingomyelin species
in the MSA-affected white matter (Figure 2A). The level
of almost all sphingomyelin species was selectively de-
creased (or showed a trend for decrease) only in the MSA-
affected white matter compared to controls (Figure 2B,C);
the decrease was substantial, i.e. 40 – 63%. A comparison
of the total sphingomyelin level (sum of all sphingomyelin
species) clearly showed a significant and selective differ-
ence between the two groups only in the MSA-affected
white matter (Figure 2D). The relative sphingomyelin
levels in VC and MC white matter were also assessed. In
controls, the level of sphingomyelin was 4.3 fold higher in
MC compared to VC white matter, whereas in MSA the
level of sphingomyelin was only 2.0-fold higher in MC
compared to VC white matter (Figure 2E), indicating, once
again, a selective decrease in sphingomyelin levels in the
MSA-affected white matter.
To evaluate whether the distribution of different
sphingomyelin species changed with MSA, the level of
each sphingomyelin species was calculated as a percent-
age of total sphingomyelin level in the two white matter
regions. Overall, the distribution of sphingomyelin spe-
cies was similar in the two groups in both white matter
regions (Figure 3). No significant shift in white matter
fatty acid chain length/content was evident with MSA. It
was interesting to note that the distribution of white
matter sphingomyelin species was overall similar in the
two regions evaluated. These data show that the absolute
levels, and not distribution, of white matter sphingomye-
lin species are altered by MSA.
Decreased sulfatide levels in MSA white matter
Similarly, we analyzed sulfatide levels in the same white
matter tissue samples; sulfatide is thought to play a major
role in myelin function and stability, which is important in
MSA pathogenesis. A bubble plot shows the decrease in
volume size of individual sulfatide species in MSA-
affected white matter (Figure 4A). In MSA-affected white
matter, the level of most sulfatide species was significantly
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Figure 2 (See legend on next page.)
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Figure 2 Analysis of sphingomyelin levels in MSA and control white matter. (A) Bubble plots illustrating the mass/charge ratio (m/z),
column elution time, and relative abundance (size of the bubbles) of sphingomyelin species detected in the MC white matter. (B,C) Bar graphs
showing the absolute amounts of different sphingomyelin species in the MSA-affected (MC) and unaffected (VC) white matter. (D) A comparison
of the total sphingomyelin levels. (E) The relative sphingomyelin levels in VC and MC. Data represent mean and SE as error bars, *p < 0.05.
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(Figure 4C). As expected, a comparison of the total
sulfatide levels (sum of all sulfatide species) showed a
significant difference between the two groups only in
MSA-affected white matter (Figure 4D). The relative
levels of sulfatide in the two white matter regions were
also assessed. In controls, the level of sulfatide was 4.0-
fold higher in MC compared to VC white matter, whereas
in MSA the level of sulfatide was only 2.7-fold higher in
MC compared to VC white matter (Figure 4E).
To evaluate whether the distribution of different white
matter sulfatide species changed with MSA, each sulfa-
tide species was calculated as a percentage of total sulfa-



































































































































Figure 3 Distribution of different sphingomyelin species in the
MSA-affected (MC) and unaffected (VC) white matter.Once again, there was no significant difference in the
distribution of each sulfatide species in either of white
matter region; no shift in fatty acid chain length/content
of white matter sulfatide with MSA. These data clearly
show that the absolute levels, and not distribution, of
white matter sulfatide species are altered in MSA.
Decreased galactosylceramide levels in MSA white matter
Again, we analyzed galactosylceramide levels in the same
white matter tissue samples; galactosylceramide is a
myelin structural lipid and biosynthetic precursor to sul-
fatide. Decreased abundance of galactosylceramide spe-
cies in MC white matter of MSA cases is illustrated in a
bubble plot (Figure 6A). In MSA-affected white matter,
the level of most galactosylceramide species was signifi-
cantly decreased, i.e. 55 – 69% (Figure 6B), whereas in un-
affected white matter, no significant difference was
detected (Figure 6C). A comparison of the total white mat-
ter galactosylceramide levels (sum of all galactosylcera-
mide species) showed a significant difference in the two
groups only in MSA-affected white matter (Figure 6D).
The level of galactosylceramide was 4.9-fold higher in MC
compared to VC white matter in controls, and only 1.7-
fold higher in MSA (Figure 6E). Once again, there was no
significant difference in the distribution of each galactosyl-
ceramide species in either of the white matter regions
(Figure 7). In addition, we have analyzed two more lipids,
sphingosine and sphingosine 1-phosphate, to determine
whether changes to lipid levels are universal or specific to
certain lipids. We found that neither sphingosine nor
sphingosine 1-phosphate levels changed in the MC white
matter of MSA (Figure 8), suggesting that not all lipid
metabolism is altered.
Analysis of α-synuclein expression in MSA white matter
Since lipid levels were selectively decreased in the MSA-
affected white matter and given the fact that α-synuclein
aggregation process is affected by lipid level/composition,
we were interested if α-synuclein expression is altered in
the MSA-affected white matter. Aggregated α-synuclein is
a major component of GCIs in MSA oligodendrocytes
(Figure 1A) and is thought to play a pivotal role in MSA
pathogenesis. Using the same tissue samples that were
used in the lipid analysis, we isolated mRNA and soluble
cytosolic protein and measured α-synuclein expression by
qPCR and western blotting. The mRNA expression of α-
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Figure 4 (See legend on next page.)
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Figure 4 Analysis of sulfatide levels in MSA and control white matter. (A) Bubble plots illustrating the mass/charge ratio (m/z), column
elution time, and relative abundance (size of the bubbles) of sulfatide species detected in the MC white matter. (B,C) Bar graphs showing the
absolute amounts of different sulfatide species in the MSA-affected (MC) and unaffected (VC) white matter. (D) A comparison of the total sulfatide
levels. (E) The relative sulfatide levels in VC and MC. Data represent mean and SE as error bars, *p < 0.05.
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white matter (Figure 9A). The level of soluble cytosolic
α-synuclein protein was not significantly altered in the
MSA tissues (Figure 9B,C).
Discussion
This quantitative case–control analysis provides novel
insight into the altered myelin lipid milieu found in
MSA-affected white matter. Total sphingomyelin levels
were selectively decreased in the disease-affected white
matter. Sphingomyelin is derived from ceramide through
the action of sphingomyelin synthases. It is the most abun-
dant sphingolipid in biological membranes and thus has a
functional significance in almost all tissues. The myelin
membrane of oligodendrocytes is particularly enriched with
sphingomyelin. Since myelin comprises the bulk of lipid



























































































Figure 5 Distribution of different sulfatide species in the MSA-affectea much greater extent in the latter – total sphingomyelin
content of whole brain homogenates is most likely a reflec-
tion of oligodendrocyte lipid metabolism.
Galactosylceramide and sulfatide levels were also
selectively reduced in MSA-affected white matter. Cer-
amide galactosyltransferase (CGT) converts ceramide to
galactosylceramide, which can be further modified to
sulfatide through the action of a sulfotransferase. In con-
trast to sphingomyelin synthases, CGT has a restricted
expression pattern with high concentration in oligoden-
drocytes, Schwann cells, kidney, testes and intestine
[29]. Although there are no lipid species exclusively
present in myelin, galactosylceramide and sulfatide are
the most typical myelin lipids with concentrations in
white matter approximately 10-fold higher than grey
matter [30]. Thus the reduction of total galactosylcera-
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Figure 6 (See legend on next page.)
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Figure 6 Analysis of galactosylceramide levels in MSA and control white matter. (A) Bubble plots illustrating the mass/charge ratio (m/z),
column elution time, and relative abundance (size of the bubbles) of galactosylceramide species detected in the MC white matter. (B,C) Bar
graphs showing the absolute amounts of different galactosylceramide species in the MSA-affected (MC) and unaffected (VC) white matter. (D) A
comparison of the total galactosylceramide levels. (E) The relative galactosylceramide levels in VC and MC. Data represent mean and SE as error
bars, *p < 0.05.
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lipids is disrupted in the disease process along with
sphingomyelin. Whilst our results clearly indicate a loss
of myelin lipids in MSA-affected white matter, we can-
not rule out the possibility that neuronal membrane
lipids that are not present in myelin, such as certain gan-
gliosides, also decline significantly, as these lipids were
not assayed in the current study. However, there was no
reduction in levels of the signaling lipids sphingosine
and sphingosine 1-phosphate in MC white matter of
MSA brains. These lipids represent a different branch of
basic sphingolipid metabolism that is apparently un-
affected in MSA, indicating that MSA does not adversely
impact on all aspects of lipid metabolism.
Sphingomyelin and sulfatide species in mammalian
cells display high variability in the N-acyl fatty acid
chain, which ranges in length from C14 to C26 in all or-
gans except skin, where the N-acyl chain is often longer.



















































































































Figure 7 Distribution of different galactosylceramide species in the Mof the common precursor molecule ceramide, which is
regulated by six different ceramide synthase enzymes
(CerS), each the product of a unique gene (reviewed in
[31]). CerS catalyze the N-acylation of sphinganine or
sphingosine with one of several possible fatty acyl-CoAs to
produce dihydroceramide and ceramide respectively. The
six CerS have distinct but overlapping acyl-chain prefer-
ence, characterization of which has advanced understand-
ing of the regulation of ceramide synthesis [32-37].
However, the biological significance of the length of fatty
acid found in different ceramide and sphingolipid species
remains obscure. It has been proposed that the fatty acid
composition of ceramide and its derivatives could influ-
ence the biophysical properties of the membrane lipid bi-
layer or the activation of different lipid signaling pathways
[38,39]. Due to the prominence of ceramide derivatives in
the CNS lipid milieu, there is increasing interest in the
role of fatty acid chain variants in neurological physiology
























































































































SA-affected (MC) and unaffected (VC) white matter.




































A       Sphingosine B   Sphingosine 1-phosphate 
Figure 8 Analysis of sphingosine and sphingosine 1-phosphate levels in MSA and control white matter. Bar graphs showing the absolute
amounts of sphingosine (A) and sphingosine 1-phosphate (B) in the MSA-affected (motor cortex) and unaffected (visual cortex) white matter.
Data represent mean and SE as error bars.
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our results concerning the differential expression of
sphingomyelin and sulfatide subspecies in MSA compared
with control brain samples is necessarily speculative.
With increasing age levels of very long chain C24 fatty
acids in sphingomyelin increase, while those of C18
acids diminish [40]. Myelin galactosylceramide and sul-
fatide are also enriched with very-long chain fatty acids
(C22-C24) [30]. Becker and colleagues [41] studied the cell
and age-specific expression of CerS by means of Northern
blot, quantitative PCR and in situ hybridization. Cer2,
which uses very long chain acyl CoAs (C22-24) for
ceramide synthesis, was abundantly expressed in all white
matter tracts of the mouse brain and in situ hybridization
confirmed strong expression in oligodendrocytes. In
addition the phenotype of a CerS2 knockout mouse fea-
tured progressive myelin disorganization including failure
of compaction and loss of myelin basic protein (MBP)
[42]. Thus sphingolipids with long chain fatty acids,
derived from CerS2 acylated precursors, appear to be
essential for myelin production and maintenance.
In the present study we can observe that C24-
sphingomyelin predominates in oligodendrocyte-rich
white matter and the C24 variant of the myelin-typical
lipid sulfatide is also abundant in white matter. This cor-
roborates the previously reported enrichment of very-long
chain fatty acids in myelin sphingolipids. However, the re-
ductions in particular sphingolipid species observed in
MSA-affected white matter compared to controls do not
appear to be limited to a specific acyl-chain variant of
sphingomyelin or sulfatide. This contrasts with the select-
ive findings [40] of specific sphingolipid variant derange-
ment in neurodegenerative conditions. The present results
may point to a more general secondary dysregulation of
myelin membrane components in MSA pathogenesis ra-
ther than a specific derangement of oligodendrocyte
sphingolipid synthesis. Studies of CerS activities and otherregulatory factors in sphingolipid synthesis are needed to
further characterize the role of specific fatty acid chain
variants in MSA and other conditions.
Song and colleagues observed abnormal relocalization
and breakdown of myelin-associated proteins, p25α and
MBP, which appeared to precede visible GCIs formation
in affected oligodendrocytes [15]. The pathogenic pro-
tein α-synuclein is a major component of GCIs in MSA
oligodendrocytes and we show that its expression at the
transcriptional level was upregulated selectively in the
MSA-affected white matter. The soluble cytosolic α-
synuclein level was unaltered in the MSA tissues, indi-
cating that α-synuclein present in MSA oligodendrocytes
is likely to be in insoluble aggregated form, as a compo-
nent of GCIs, which we clearly observed in the MSA-
affected white matter (Figure 1A,B). The solubility of
α-synuclein in MSA is quite different from that of PD or
DLB. In MSA brain, α-synuclein is present mainly as
SDS-soluble (not insoluble) accumulation. Detergent-
insoluble α-synuclein is usually not detected [43]. This
is in contrast to PD and DLB, in which α-synuclein is
clearly detected in urea extracts of SDS-insoluble brain
tissues [43,44]. The cross-sectional observations of the
present case–control study cannot be used to make
explicit temporal inferences regarding lipid dysregula-
tion in MSA pathogenesis. Nonetheless depletion of
sulfatide and sphingomyelin would fit well as precur-
sors to myelin protein disruption in the working model
of disease events.
The origin of α-synuclein in the oligodendrocyte GCIs
remains enigmatic. Although the evidence of significant
physiological expression of α-synuclein in mature oligo-
dendrocytes is conflicting [45-47], it has been proposed
that upregulation of the SNCA gene in these cells could
be the cause of GCI formation. However, there appears to
be no dysregulation of α-synuclein expression in the MSA
















































Figure 9 Analysis of α-synuclein expression in MSA (n = 8) and
control (n = 10) white matter. (A) mRNA expression of α-synuclein
as measured by qPCR; data represent mean and SE as error bars,
*p < 0.05. (B) Soluble cytosolic α-synuclein protein as measured by
western blotting of Control 1–4 and MSA 1–4. β-actin was used as a
loading control. (C) Relative optical density of α-synuclein-
immunoreactive protein bands as quantified using ImageJ software.
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been generated by α-synuclein overexpression in the oli-
godendrocytes of mouse brains [48-50]. Alternatively, ab-
errant uptake of α-synuclein protein from the extracellular
environment has also been proposed as a possible mech-
anism of GCI formation [45,51,52].
Separate lines of evidence from transgenic mouse
models support the specific functional importance of
myelin sulfatide content in the CNS. CGT knockout
mice lacking both galactosylceramide and sulfatide have
a neuropathological phenotype with tremor and severe
motor weakness [22,23]. However, these deficits are
abolished by targeted restoration of CGT function to oli-
godendrocytes only. Myelin composition and stability is
also disturbed in mice lacking sulfatide with normal
galactosylceramide levels, showing relatively normal
early development of oligodendrocytes with later defects
in myelin compaction and maintenance of protein do-
mains in nodal regions [16].
Depletion of sphingomyelin in the MSA disease process
is consistent with the observation of transcriptional upreg-
ulation of the lipid transporter ABCA8 in MSA-affected
white matter. Previously, a region and age-specific study
of ABCA8 expression in the human brain [20] showed
selective enrichment in white matter regions and upregu-
lation across the human life-span correlating with age-
associated expansion of myelin [53,54]. In vitro ABCA8
was able to significantly stimulate both sphingomyelin
synthase 1 expression and sphingomyelin production in a
human oligodendrocyte cell line [20]. Thus ABCA8 is
likely to be involved in oligodendrocyte sphingolipid me-
tabolism and myelin synthesis and maintenance. In con-
junction with the findings of the present study, ABCA8
upregulation may be a compensatory response to disturb-
ance of sphingolipid metabolism.
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